Oriana Nanni (O Nanni)

Scopus Author ID ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 11

Top Venues

The oncologist

Cancers

Journal of medical Internet research

Journal of the National Cancer Institute

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori Srl

Università degli Studi di Modena e Reggio Emilia (MSC)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori Srl Feb 01 2007

Italy

direttore :: unità di Biostatistica e Sperimentazioni Cliniche UBSC

Education History

Università degli Studi di Modena e Reggio Emilia

Italy

MSC :: Medicina

Publications

Francesco Schettini, Michela Palleschi, Francesca Mannozzi, Fara Brasó-Maristany, Lorenzo Cecconetto, Patricia Galván, Marita Mariotti, Alessia Ferrari, Emanuela Scarpi, Anna Miserocchi, Oriana Nanni, Esther Sanfeliu, Aleix Prat, Andrea Rocca, Ugo De Giorgi
CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial. The oncologist 29 (5) (2024)
Francesco Schettini, Michela Palleschi, Francesca Mannozzi, Fara Brasó-Maristany, Lorenzo Cecconetto, Patricia Galván, Marita Mariotti, Alessia Ferrari, Emanuela Scarpi, Anna Miserocchi, Oriana Nanni, Esther Sanfeliu, Aleix Prat, Andrea Rocca, Ugo De Giorgi
CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial. The oncologist (2024)
Francesco Schettini, Michela Palleschi, Francesca Mannozzi, Fara Brasó-Maristany, Lorenzo Cecconetto, Patricia Galván, Marita Mariotti, Alessia Ferrari, Emanuela Scarpi, Anna Miserocchi, Oriana Nanni, Esther Sanfeliu, Aleix Prat, Andrea Rocca, Ugo De Giorgi
CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial. The oncologist 29 (5) (2024)
Francesco Schettini, Michela Palleschi, Francesca Mannozzi, Fara Brasó-Maristany, Lorenzo Cecconetto, Patricia Galván, Marita Mariotti, Alessia Ferrari, Emanuela Scarpi, Anna Miserocchi, Oriana Nanni, Esther Sanfeliu, Aleix Prat, Andrea Rocca, Ugo De Giorgi
CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial. The oncologist 29 (5) (2024)
Francesco Schettini, Michela Palleschi, Francesca Mannozzi, Fara Brasó-Maristany, Lorenzo Cecconetto, Patricia Galván, Marita Mariotti, Alessia Ferrari, Emanuela Scarpi, Anna Miserocchi, Oriana Nanni, Esther Sanfeliu, Aleix Prat, Andrea Rocca, Ugo De Giorgi
CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial. The oncologist 29 (5) (2024)
Emanuela Scarpi, Oriana Nanni, Marco Maltoni
Development and Validation of the PaP Score Nomogram for Terminally Ill Cancer Patients. Cancers 14 (10) (2022)
Isacco Montroni, Giampaolo Ugolini, Nicole M Saur, Siri Rostoft, Antonino Spinelli, Barbara L Van Leeuwen, Nicola De Liguori Carino, Federico Ghignone, Michael T Jaklitsch, Ponnandai Somasundar, Anna Garutti, Chiara Zingaretti, Flavia Foca, Bernadette Vertogen, Oriana Nanni, Steven D Wexner, Riccardo A Audisio, null null
Quality of Life in Older Adults After Major Cancer Surgery: The GOSAFE International Study. Journal of the National Cancer Institute 114 (7) (2022)
Alessandro Passardi, Patrizia Serra, Caterina Donati, Federica Fiori, Sabrina Prati, Roberto Vespignani, Gabriele Taglioni, Patrizia Farfaneti Ghetti, Giovanni Martinelli, Oriana Nanni, Mattia Altini, Giovanni Luca Frassineti, Martina Vittoria Minguzzi
An Integrated Model to Improve Medication Reconciliation in Oncology: Prospective Interventional Study. Journal of medical Internet research 23 (12) (2021)
Manlio Monti, Paolo Morgagni, Oriana Nanni, Massimo Framarini, Luca Saragoni, Daniele Marrelli, Franco Roviello, Roberto Petrioli, Uberto Fumagalli Romario, Lorenza Rimassa, Silvia Bozzarelli, Annibale Donini, Luigina Graziosi, Verena De Angelis, Giovanni De Manzoni, Maria Bencivenga, Valentina Mengardo, Emilio Parma, Carlo Milandri, Gianni Mura, Alessandra Signorini, Gianluca Baiocchi, Sarah Molfino, Giovanni Sgroi, Francesca Steccanella, Stefano Rausei, Ilaria Proserpio, Jacopo Viganò, Silvia Brugnatelli, Andrea Rinnovati, Stefano Santi, Giorgio Ercolani, Flavia Foca, Linda Valmorri, Dino Amadori, Giovanni Luca Frassineti
Preoperative or Perioperative Docetaxel, Oxaliplatin, and Capecitabine (GASTRODOC Regimen) in Patients with Locally-Advanced Resectable Gastric Cancer: A Randomized Phase-II Trial. Cancers 12 (10) (2020)
Oriana Nanni, D Amadori, A De Censi, A Rocca, A Freschi, A Bologna, L Gianni, F Rosetti, L Amaducci, L Cavanna, F Foca, S Sarti, P Serra, L Valmorri, P Bruzzi, D Corradengo, A Gennari, null null
Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial. Breast cancer research and treatment 174 (2) (2018)
Annalisa Pezzi, Michele Cavo, Annibale Biggeri, Elena Zamagni, Oriana Nanni
Inverse probability weighting to estimate causal effect of a singular phase in a multiphase randomized clinical trial for multiple myeloma. BMC medical research methodology 16 (1) (2016)

Oriana Nanni.css-eqlu8i{font-size:small;padding-left:4px;} (O Nanni)

Publication Activity (10 Years)

Top Topics

Top Venues

Oriana Nanni (O Nanni)